Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)
Quality of Life
DIETARY_SUPPLEMENT: Oncoxin|DRUG: Suranix
Number of patients who have prolonged survival, To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks, 24 weeks
Reduction in serum alpha-fetoprotein level and decrease in tumor size, To see whether Oncoxin plus Surafenib results in reduction in serum alpha-fetoprotein level in ng/ml and decrease in tumor size in mm in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin plus Surafenib for 24 weeks., 24 weeks
To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular carcinoma

To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is improved survival in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib